EIGR
(NASDAQ)
8.88
-0.1000   (-1.11%)
Pre-market: .00 -8.88 (-100.00%)
Volume (24h) Market Cap. Day Range 52w Range
278.57K 259.68M 8.72 - 9.17 4.61 - 15.82
Oct-16-20 02:01PM Eiger (EIGR) Up on Positive Results From Coronavirus StudyZacks
Oct-15-20 07:24PM Why Eiger BioPharmaceuticals Stock Skyrocketed TodayMotley Fool
12:00PM Eiger BioPharmaceuticals Announces Positive Results of Investigator Sponsored Randomized Controlled Trial at University of Toronto with Peginterferon Lambda in Outpatients with Mild to Moderate COVID-19PR Newswire
Sep-29-20 11:42AM Eiger Down on Disappointing Results From Coronavirus StudyZacks
Sep-28-20 07:47PM Why Eiger BioPharmaceuticals Stock Sank TodayMotley Fool
07:07PM Hedge Funds Are Done Buying Eiger BioPharmaceuticals, Inc. (EIGR)Insider Monkey
Sep-28-20 12:00PM Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19PR Newswire
Sep-15-20 12:54PM Implied Volatility Surging for Eiger BioPharmaceuticals (EIGR) Stock OptionsZacks
Sep-09-20 01:36PM Billionaire David Shaw Pours Money Into 3 “Strong Buy” StocksTipRanks
Sep-01-20 12:00PM Eiger Bio to Participate in September 2020 Investor ConferencesPR Newswire
Aug-31-20 12:00PM Eiger Announces Peginterferon Lambda - Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study in Late Breaker Session at The Digital International Liver Congress™ 2020PR Newswire
Aug-19-20 12:49PM Eiger BioPharmaceuticals (EIGR) Catches Eye: Stock Jumps 8.6%Zacks
Aug-17-20 11:40AM Insider Buying: The Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Founder Just Bought 4.7% More SharesSimply Wall St.
Aug-06-20 08:05PM Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business UpdatePR Newswire
Aug-03-20 12:00PM Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor ConferencesPR Newswire
Jul-17-20 04:16PM Is Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Popular Amongst Institutions?Simply Wall St.
Jul-13-20 12:14AM Did Hedge Funds Make The Right Call On Eiger BioPharmaceuticals, Inc. (EIGR) ?Insider Monkey
Jul-08-20 04:00PM Eiger BioPharma (EIGR) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks
Jun-24-20 12:32PM Why Eiger BioPharmaceuticals (EIGR) Stock Might be a Great PickZacks
Jun-08-20 05:22PM Hedge Funds Can’t Buy Enough Of Eiger BioPharmaceuticals, Inc. (EIGR)Insider Monkey
May-29-20 08:05PM Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020PR Newswire
May-26-20 08:05PM Eiger to Present at Jefferies Virtual Healthcare Conference 2020PR Newswire
May-20-20 12:12PM The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic TestBenzinga
May-19-20 08:05PM Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid LaminopathiesPR Newswire
May-15-20 12:57PM Is Eiger BioPharmaceuticals (EIGR) Stock a Solid Choice Right Now?Zacks
Apr-30-20 12:00PM Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon LambdaPR Newswire
Apr-22-20 02:05PM Will Eiger BioPharmaceuticals Continue to Surge Higher?Zacks
Apr-09-20 10:08PM Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delaysAmerican City Business Journals
Apr-01-20 08:05PM Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 PandemicPR Newswire
Mar-24-20 02:25PM Eiger Completes NDA Submission of Progeria Drug LonafarnibZacks
Mar-23-20 12:00PM Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid LaminopathiesPR Newswire
Mar-20-20 10:45AM Insider Buying: The Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Founder Just Bought US$151k Worth Of SharesSimply Wall St.
Mar-13-20 12:00PM Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdatePR Newswire
Jan-19-20 08:04PM Top Insider Buys Highlight for the Week of Jan. 17GuruFocus.com
Jan-15-20 10:24AM Trade Alert: The Chairman Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Thomas Dietz, Has Just Spent US$56k Buying SharesSimply Wall St.
Jan-07-20 01:00PM Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial OfficerPR Newswire
Jan-06-20 01:00PM Eiger Updates on 2019 Progress and 2020 Milestones ExpectedPR Newswire
Dec-16-19 10:15PM Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid LaminopathiesPR Newswire
Dec-07-19 06:33AM Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR)Insider Monkey
Nov-15-19 01:00PM Eiger to Present at Jefferies 2019 London Healthcare ConferencePR Newswire
Nov-12-19 01:45PM Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019PR Newswire
Nov-11-19 02:58PM Is Eiger BioPharmaceuticals, Inc. (EIGR) A Good Stock To Buy?Insider Monkey
Nov-07-19 09:05PM Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business UpdatePR Newswire
Oct-21-19 01:00PM Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019PR Newswire
Oct-09-19 01:47PM Do Institutions Own Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?Simply Wall St.
Sep-27-19 12:00PM Eiger to Present at Cantor 2019 Global Healthcare ConferencePR Newswire
Aug-29-19 08:05PM Eiger BioPharmaceuticals to Participate in September ConferencesPR Newswire
Aug-20-19 12:00PM Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus InfectionPR Newswire
Aug-08-19 08:05PM Eiger BioPharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business UpdatePR Newswire
Aug-05-19 12:00PM Eiger BioPharmaceuticals to Participate in Investor Conferences in AugustPR Newswire
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Cap:    |  Volume (24h):